key: cord-1048335-81oypg1r
authors: Rodríguez-Baño, Jesús; Rossolini, Gian Maria; Schultsz, Constance; Tacconelli, Evelina; Murthy, Srinivas; Ohmagari, Norio; Holmes, Alison; Bachmann, Till; Goossens, Herman; Canton, Rafael; Roberts, Adam P.; Henriques-Normark, Birgitta; Clancy, Cornelius J.; Huttner, Benedikt; Fagerstedt, Patriq; Lahiri, Shawon; Kaushic, Charu; Hoffman, Steven J.; Warren, Margo; Zoubiane, Ghada; Essack, Sabiha; Laxminarayan, Ramanan; Plant, Laura
title: AMR research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic
date: 2021-03-01
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2021.02.013
sha: 9519deaf06d57f900fb0f5ff22ed62649f310a49
doc_id: 1048335
cord_uid: 81oypg1r

nan

the COVID-19 and future pandemics, in order to safeguard against an uncontrolled rise in AMR.

The priority during the COVID-19 pandemic has been treating patients and avoiding acquisition of SARS-CoV-2 by healthcare personnel whilst maintaining functionality of the healthcare systems. Within healthcare, there has been a need to redirect personnel, resources and attention to COVID-19 diagnosis and management. AMR surveillance and screening programmes to detect colonisation by resistant organisms have been compromised due to shortage of personnel and the need to redirect molecular diagnostic platforms, reagents, tracking and tracing from AMR surveillance to COVID-19 diagnostics.

It has been reported that only 7-8% of hospitalised COVID-19 patients were diagnosed with a bacterial or fungal infection [1, 2, 3] , while antibiotic use in COVID-19 patients has been considerably high: 71.9% (95% CI: 56.1-87.7) [3] . Further studies using molecular techniques on samples from ventilated and non-ventilated COVID-19 patients are needed.

Whether new or evolving AMR in COVID-19 patients will emerge in areas with low previous rates should be examined in retrospective and prospective clinical and microbiology studies.

Simultaneously managing the acute COVID-19 pandemic and escalating AMR COVID-19 has illustrated the vulnerability of our healthcare systems. This is even more noticeable in Low and Middle Income Countries (LMICs) and in resource-constrained settings less prepared to deal with pandemics or other emergencies [4] [5] [6] . Local, national and international scale resistance data is needed to help researchers better understand potential disruptions in stewardship and surveillance efforts, and highlight the early emergence of resistance due to antibiotic use linked to COVID-19 and secondary infections.

Co-managing multiple infectious disease threats simultaneously is a further challenge for LMICs. Laboratory infrastructure, surveillance and diagnostic capacity for both COVID-19 J o u r n a l P r e -p r o o f and AMR are often unreliable and infection prevention and control policies, practice and personnel are sub-optimal and, or, unsustainable [7] . Regulated antibiotic use is difficult to enforce where there is poor access to antibiotics overall, while socio-behavioural interventions such as physical distancing and hand hygiene can be limited, especially in areas with high population densities with limited access to clean water and sanitation services Thus, an exit strategy from COVID-19 for many LMICs may not be pharmacologically based in the short term and more community-based strategies are currently being explored [8] .

A critical lesson from the COVID-19 pandemic is the importance of embedding research in the response. Supporting good quality implementation research could help understand not only what has worked, but also how and why an intervention was successful. While research on COVID-19 due to the pandemic has progressed, research in other fields including AMR has been deprioritised, delayed, or even halted. Delays limit scientists to meet deadlines and targets within projects, and restrict sharing of information and networking activities.

Funding agencies across the globe have given research grant extensions; however, the longterm impact on AMR research is yet to be understood and factors such as the effect on early career researchers may take years to manifest. As solidarity pledges emerge to address COVID-19, so too must efforts to openly share research and data 'on AMR, including surveillance data from the pharmaceutical industry, as incentivised by the Access to Medicine Foundation's AMR Benchmark. In order to ensure that AMR research continues to be adequately supported it is important to prioritise funds for AMR research at both national and international scales. 

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Soriano A and COVID19-researchers group. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study

Antimicrobial Resistance Benchmark

Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status

Pandemic: Effects on Low-and Middle-Income Countries

COVID-19 treatment in sub-Saharan Africa: If the best is not available, the available becomes the best

The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries

Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis

This work was founded on the Joint Programming Initiative on Antimicrobial Resistance webinar series 'AMR in a post-pandemic world'.J o u r n a l P r e -p r o o f